Protection From Acute Kidney Injury (AKI) With Basis™ Treatment
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, prospective, randomized, double-blinded, placebo-controlled
phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™
(Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients
undergoing complex aortic aneurysm repair and open aortic arch reconstruction.